The Prognostic Significance of Frequency of T790M Alleles and Blood NGS profile in EGFR T790M mutation patients with non-small cell lung cancer with Lazertinib treatment.

Asan Medical Center0 个研究点目标入组 120 人开始时间: 待定最近更新: 2022年1月11日

适应症

试验速览

暂无简介。

•1. Male or female subjects 20 years of age or older
•2. Histologically or cytologically confirmed patients with advanced or metastatic NSCLC
•3. Patients confirmed as positive for T790M mutation as a result of plasma EGFR test
•4. Patients who were treated by the first and the second generation EGFR-TKI for the treatment of NSCLC and are planning to initiate the treatment of Lazertinib
•5. Patients with functional status score (Performance Status, PS) for 0-2 points according to the Eastern Cooperative Oncology Group (ECOG) for the past 2 weeks
•6. The participants who provide the signed and dated written informed consent document prior to specific procedures for this study.

•1. Patients already being treated or treated with the 3rd generation EGFR tyrosine kinase inhibitors (TKIs)
•2. All malignancies other than prior or concurrent disease under study
•However, except for the following : patients who have been adequately treated for non-melanomatous skin cancer , carcinoma in situ of the cervix , ductal carcinoma in situ of the breast , thyroid cancer, or malignancies that have been adequately treated and have been in remission for more than 3 years and are curatively treated

发起方